Introduction
Of about 8.2 million people living in Switzerland, up to 360,000 suffer from psoriasis [1, 2] , and between 8, 200 and 32,400 may have moderate-to-severe psoriasis. The latter condition has a profound impact on the quality of life of patients and their respective risk to develop or worsen diseases of civilization such as cardiovascular events [3, 4] . Although randomized controlled trials have shown efficacy of most systemic treatments [5] [6] [7] , profound knowledge about long-term outcomes and optimal treatment strategies in specific patients under real-world conditions are lacking in Switzerland. The Swiss Dermatology Network for Targeted Therapies (SDNTT) registry was established in 2011 to study the efficacy and safety of approved systemic therapies and patient-reported measures in real-life settings over time [8] . In contrast to randomized clinical trials, patient registries have less stringent inclusion criteria and allow to follow heterogeneous patient populations with varying disease severity and medications for long periods of time [9, 10] . We were particularly interested to compare the development of the PASI (Psoriasis Area and Severity Index) and DLQI (Dermatological Life Quality Index) within the first year of onset of treatment in all Swiss psoriasis patients included in the SDNTT who were treated with biologics only, biologics and conventional systemic therapeutics (simultaneously) or therapy adaptation (switching from one type to the other) with those who were treated with conventional systemic therapeutics only. The SDNTT is a noninterventional observational registry based on an electronic case report form provided by the Centre of Excellence for Health Services Research in Dermatology (CVderm, Competenzzentrum Versorgungsforschung in der Dermatologie) at the University Medical Center Hamburg Eppendorf, Germany. The documentation is managed using a patient-based database as a registry.
Patients and Methods
For further details, see the supplementary materials (for all online suppl. material, see www.karger.com/doi/10.1159/000455042 [11] [12] [13] [14] [15] [16] [17] [18] ( Fig. 1 ) . 
Results
Out of the 334 patients included in the SDNTT registry ( Fig. 1 Table 1 ). The average age was 47.1 years (SD 15) with only 39.2% women. The average body mass index (BMI) was 27.0 (SD 6.4), and the mean prior disease duration was 15 years (SD 13.5). Psoriasis arthritis was present in 23.9% over all groups.
Primary End Point PASI
Neither the biologic nor the combined treatment cohort significantly differed from the conventional systemic therapeutics cohort with regard to absolute PASI ( Table 2 ) .
Patients with therapy adaptation had on average a higher PASI than those with conventional systemic therapeutics ( p = 0.003). At visits 3 and 4, the PASI was generally lower than at visit 2 (visit 3 vs. visit 2, p = 0.0019; visit 4 vs. visit 2, p < 0.001). The development of PASI values within 12 months was similar in all cohorts, as indicated by the non-significant interaction terms between treatment cohorts and visits. Moreover, there was a significant positive association between the PASI at baseline (visit 1) and the PASI at visits 2-4. The results from the statistical model of the log-transformed PASI are visualized on the original scale for a "model patient" in Figure 2 .
Secondary End Points PASI75 and PASI90
Both the odds (and thus the probability) of a PASI90 and PASI75 were significantly increased at visits 3 and 4 compared to visit 2 (Appendix Tables). The odds of PASI75 was significantly increased with higher values of the PASI at baseline ( p < 0.001), whereas this effect was non-significant for the PASI90. This indicates that patients with higher baseline PASI were more likely to experience a reduction of the PASI by at least 75%. Moreover, the odds of PASI90 was significantly decreased with a higher BMI ( p = 0.041) and increased with combined therapy compared to conventional systemic therapeutics ( p = 0.043). The results for the binary end points PASI75 and PASI90 are visualized as probabilities for a "model patient" in Figures 3 and 4 .
Secondary End Point DLQI
Patients with biologic treatment reached a lower DLQI than those with conventional systemic therapeutics ( p = Note that due to missing values, the number of measurements is lower than the total number (top row) for some characteristics. Con., conventional; Bio., biologics; Comb., combination; Ada., adaptation; PSO, psoriasis.
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Discussion
This study investigated PASI and DLQI changes over 12 months after initiation of a systemic therapy in all psoriasis patients registered in the SDNTT registry from May 2011 to December 2014. The patient number in this study was relatively low compared to older registries of larger countries [19] ; however, the results reflect the real-world situation of registered and treated patients in Switzerland. Within 12 months after the start of therapy, patients with moderate-to-severe psoriasis who were treated with biologics or combined therapy showed essentially equivalent developments of PASI values compared to those who were treated with conventional systemic therapeutics only. In comparison to those on conventional systemic therapeutics, a larger proportion of patients on biologics reached PASI75 and PASI90; however, the differences were not significant over the 12-month period. This could be due to the interrater variation by different investigators for the PASI assessment and a direct consequence that the PASI has a low resolution below values of 5 [13] ( Fig. 2 ) . As expected, patients who had to adapt treatment did not reach comparable PASI values within 12 months, as this cohort understandably represents more difficult-to-treat patients. Moreover, the limited number of patients under combined treatment had an increased probability to reach PASI90. However, real-world outcome data on combined therapy are rare, some authors concluded that combined therapy might have at least some potential benefit in patients with joint involvement, methotrexate toxicity or in cases of monotherapy failure [20] .
In contrast to PASI development patients treated with biologics reached significantly lower DLQI values within 12 months compared to those treated with conventional systemic therapeutics. As in the biologic patient group psoriatic arthritis was slightly overrepresented ( Table 1 ) , the greater DLQI reduction might reflect the patient benefit of biologics on improvement of joint complaints. Presumably reduced monitoring visits, lower injection frequencies and higher drug tolerability of biologically treated patients could be feasible arguments for the better DLQI improvements. Previous studies comparing objective and subjective assessments in psoriasis patients on biologics and conventional systemic agents have been rather limited [21] . In line with our results one report also revealed more pronounced DLQI improvements in patients receiving biologics for 12 months compared to those who were on conventional systemic therapeutics [22] . We consider this finding important since the decision to initiate biologic treatment for physicians and health insurances still seems to be more strongly dependent on PASI values than on DLQI scores [23] . As stated in the recently published Swiss S1 guidelines and also based on our own results, DLQI values should be critically taken into account particularly in patients with low- er PASI values suffering from severe involvement of difficult-to-treat locations such as the nails, scalp, genitals, palmoplantar areas or joint involvement and in those patients complaining of severe pruritus. This study has potential limitations. Due to missing values on outcomes and covariates used in the statistical models, the number of patients included in the analysis was relatively low compared to other registries [24] . However, we believe that our failure to detect significant differences regarding the primary end point PASI between either biologics or combined therapy and conventional systemic therapeutics is rather due to the small and clinically irrelevant effect sizes (e.g., PASI for biologics <0.5 points lower than for conventional systemic therapeutics after 3 months, at visit 2; Fig. 2 ) than due to the relatively small sample size. The strength of this register-based study from Switzerland is that it analyses the subjective and objective disease activity under real-world conditions using robust statistical models that account for the effects of important patient characteristics, which reduce the problem of confounding. Nevertheless, some characteristics that might contribute to the outcome as well, such as details of the psoriasis location, were not captured in the SDNTT registry.
Taken together, this study shows that after 1 year of treatment, biologics are superior in improving the subjective disease burden compared to conventional systemic drugs.
Statement of Ethics
This research study protocol was ethically conducted in accordance with the World Medical Association Declaration of Helsinki and has been approved by the University Hospital of Basel Ethical Review Board, Switzerland. The project was conducted with informed written consent from all patients.
Disclosure Statement
The SDNTT registry has received financial support from Abbvie, Jansen and Pfizer. The sponsors had no access to data. Data collection, study design, interpretation, and analysis have been carried out with the authors' independence. All authors have participated in industry-sponsored meetings, received travel support, or served as speaker or investigator for one or more of the following companies: AbbVie, Janssen, Pfizer, Novartis, Celgene, MSD. The authors certify that they have no relevant affiliations with or involvement in any organization or entity with any financial interest (such as honoraria, employment, stock ownership, or other equity interest, and expert testimony or patent-licensing arrangements) that would contribute to any bias in the subject matter discussed in this paper. 
